Posted by Michael Wonder on 16 Feb 2017
Why drug companies don’t want President Trump to deregulate the FDA
16 February 2017 - When President Donald Trump met with big pharma CEOs at the White House last month, he offered a combination of demands and olive branches.
But the biopharma industry isn't particularly thrilled over one of his proposed gifts: a deregulated FDA that speeds drug approvals past the regulatory finish line.
You'd think that the sector would champ at the bit for a stripped down FDA. But a first-to-market advantage doesn't mean much if there's not enough of a market to capitalise on. And that's exactly what's raising concerns among a number of prominent drug company executives who fear that insurance companies would be loathe to cover an unproven treatment.
